Utpal Koppikar
Director/Board Member presso C4 THERAPEUTICS, INC.
Patrimonio netto: 172 592 $ in data 31/03/2024
Profilo
Utpal Koppikar is an Independent Director at C4 Therapeutics, Inc. He previously worked as a Director at Flexion Therapeutics, Inc. and as Vice President-Corporate & Operations Finance at Gilead Sciences, Inc. He is also the Chief Financial Officer & Senior Vice President at Atara Biotherapeutics, Inc. Mr. Koppikar holds a graduate degree from Stanford University, an undergraduate degree from the University of Maryland, and an MBA from UCLA Anderson School of Management.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 02/03/2023 | 181 978 ( 0.14% ) | 126 293 $ | 31/03/2024 | |
C4 THERAPEUTICS, INC.
0.01% | 15/06/2023 | 5 667 ( 0.01% ) | 46 299 $ | 31/03/2024 |
Posizioni attive di Utpal Koppikar
| Società | Posizione | Inizio |
|---|---|---|
| C4 THERAPEUTICS, INC. | Director/Board Member | 16/03/2022 |
Precedenti posizioni note di Utpal Koppikar
| Società | Posizione | Fine |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 31/03/2023 |
| FLEXION THERAPEUTICS, INC. | Director/Board Member | 19/11/2021 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/06/2018 |
Formazione di Utpal Koppikar
| Stanford University | Graduate Degree |
| University of Maryland | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| C4 THERAPEUTICS, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
- Borsa valori
- Insiders
- Utpal Koppikar
